Clinical trial
Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2
NCT00400374 · Emory University, Other · Completed
Key facts
| NCT number | NCT00400374 |
|---|---|
| Title | Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2 |
| Official title | Phase I Study of Secondary Primary Tumor Prevention With Epidermal Growth Factor Receptor (EGFR), Tyrosine Kinase Inhibitor Erlotinib (OSI-774, Tarceva™), and Cyclooxygenase-2 (COX-2) Inhibitor (Celecoxib) in Early Stage (Stage I/II) Squamous Cell Carcinoma of Head and Neck |
| Lead sponsor | Emory University, Other |
| Collaborators | Genentech, Inc. Industry National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | Erlotinib, Celecoxib |
| Enrollment | 10 |
| Start date | Aug 1, 2007 |
| Primary completion | Dec 1, 2012 |
| Completion | Nov 1, 2016 |
| First posted | Nov 16, 2006 |
| Last update posted | Mar 15, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: